Longitudinal liver stiffness assessment in patients with chronic hepatitis C undergoing antiviral therapy.
Fiche publication
Date publication
janvier 2012
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BRONOWICKI Jean-Pierre
Tous les auteurs :
Martinez SM, Foucher J, Combis JM, Metivier S, Brunetto M, Capron D, Bourliere M, Bronowicki JP, Dao T, Maynard-Muet M, Lucidarme D, Merrouche W, Forns X, de Ledinghen V
Lien Pubmed
Résumé
BACKGROUND/AIMS: Liver stiffness (LS) measurement by means of transient elastography (TE) is accurate to predict fibrosis stage. The effect of antiviral treatment and virologic response on LS was assessed and compared with untreated patients with chronic hepatitis C (CHC). METHODS: TE was performed at baseline, and at weeks 24, 48, and 72 in 515 patients with CHC. RESULTS: 323 treated (62.7%) and 192 untreated patients (37.3%) were assessed. LS experienced a significant decline in treated patients and remained stable in untreated patients at the end of study (P/= 7.1 kPa (P/= 9.5 and >/= 7.1 kPa vs lower values, respectively). Sustained virological responders and relapsers had a significant LS improvement whereas a trend was observed in nonresponders (mean percent change -16%, -10% and -2%, for SVR, RR and NR, respectively, P 0.03 for SVR vs NR). In multivariate analysis, high baseline LS (P
Référence
PLoS One. 2012;7(10):e47715